Aptevo Therapeutics Inc. (APVO) Financials

APVO Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 14.5 million 8.5 million
March 31, 2026 19.9 million 8.3 million
Dec. 31, 2025 27.2 million 9.8 million
Sept. 30, 2025 27.0 million 9.6 million

APVO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -5.5 million 58000
March 31, 2026 -8.0 million 57000
Dec. 31, 2025 -5.2 million 2000
Sept. 30, 2025 -6.7 million 77000

APVO Net Income

No data available :(

APVO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 9.8 million 3.3 million -
March 31, 2026 14.5 million 3.5 million 4.4 million
Dec. 31, 2025 21.6 million - 3.8 million
Sept. 30, 2025 21.1 million - 4.0 million

APVO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 1.2 million
March 31, 2026 1.1 million
Dec. 31, 2025 997830
Sept. 30, 2025 224946

APVO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 3.7 million 2.7 million -
March 31, 2026 - 3.9 million 2.9 million -
Dec. 31, 2025 - 3.5 million 2.5 million -
Sept. 30, 2025 - 4.0 million 3.6 million -

APVO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 35000
Dec. 31, 2025 -220000 81000
Sept. 30, 2025 - -

APVO Revenue by Segment
Graph available only for paid members. Upgrade to see it.

APVO

Price: $2.90

52 week price:
2.81
50.40

Earnings Per Share: 1488.13 USD

P/E Ratio: 0.00

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 73389

Ebitda: -9.5 million

Market Capitalization: 4.5 million

Links: